close

Agreements

1 242 243 244 245 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-02-01 Apeiron Biologics (Austria) Merck KGaA, , Merck Serono (Germany) hu14.18-IL2 pediatric neuroblastoma - melanoma

licensing

Cancer - Oncology Licensing agreement
2011-01-31 Newron (Italy) Merck Serono (Germany) pruvanserin and sarizotan CNS diseases

Licensing

CNS diseases Licensing agreement
2011-01-28 MDxHealth (Belgium) Pfizer (USA - NY) Newcastle University (UK) Cancer Research Technology Limited (CRT) UK biomarker predicting response to PF-01367338, drug candidate for PARP inhibition ovarian cancer breast cancer

R&D

development

Cancer - Oncology R&D agreement
2011-01-28 ALK (Denmark)Torii Pharmaceutical Co (Japan) house dust mite allergy immunotherapy products (Mitizak®, Alutard®) asthma - allergic rhinitis

development
commercialisation

Respiratory diseases - Inflammatory diseases - Allergic diseases Development agreement
2011-01-27 Bayer HealthCare (Germany) Zydus Cadila (India)

joint-venture

Gynecology - Diagnostic imaging - Cardiovascular diseases - Metabolic diseases - Cancer - Oncology Collaboration agreement
2011-01-26 Swedish Orphan Biovitrum (Sweden) Fresenius Biotech (Germany) Removab® (catumaxomab) malignant ascites in patients with EpCAM (Epithelial Cell Adhesion Molecule) positive carcinomas where standard therapy is not available or no longer feasible.

Distribution

Cancer - Oncology Distribution agreement
2011-01-25 Cerep (France) Shire (UK-USA) BioPrint® (pharmacology and ADME database)

Licensing

Licensing agreement
2011-01-25 Oxford BioTherapeutics (UK) Sanofi-Aventis (France) preclinical antibody program

Licensing

Cancer - Oncology Licensing agreement
2011-01-24 MediGene (Germany) Meditrina Pharmaceuticals (Greece) Veregen® ointment (made from the extract of green tea leaves - catechins) External genital warts

commercialisation
distribution

Gynecology - Infectious diseases Distribution agreement
2011-01-17 Domain Therapeutics (France) Merck Serono (Germany) metabotropic glutamatereceptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs Parkinson’s disease and other neurodegenerative diseases

Development
Licensing

Neurodegenerative diseases - CNS diseases Development agreement
2011-01-17 Polyplus-transfection (France)Roche Glycart (Switzerland) polyethylenimine (PEI) for in vitro transfection applications for research purposes

Licensing

Licensing agreement
2011-01-17 Faron Pharmaceuticals Ltd (Finland) Rentschler Biotechnologie GmbH (Germany) Traumakine® (FP-1201- recombinant human interferon beta-1a (IFN-beta 1a) prevention of vascular leakage in patients with acute lung injuries (ALI) and its more severe form acute respiratory distress syndrome (ARDS)

Manufacturing
Supply
Production

Respiratory diseases Production agreement
2011-01-13 MediGene AG (Germany) Laboratoires Expanscience (France ) Veregen® ointment (made from the extract of green tea leaves - catechins) external genital warts

commercialisation
marketing

Gynecology - Infectious diseases Commercialisation agreement
2011-01-13 Ipsogen (France) Stanford University (USA) LNK mutations myeloid disorders

Licensing

Cancer - Oncology Licensing agreement
2011-01-13 Cancer Research UK (UK) AstraZeneca (UK) combinations of new cancer drugs cancer

R&D
Clinical trials

Cancer - Oncology R&D agreement
2011-01-12 Sanofi-Aventis ( France) University of California, San Francisco - UCSF (USA) pain - inflammation

R&D

CNS diseases - Inflammatory diseases - Immunological diseases - Metabolic diseases R&D agreement
2011-01-12 Sanofi-Aventis ( France) University of California, San Francisco -UCSF (USA)

R&D

Cancer - Oncology R&D agreement
2011-01-11 Swedish Orphan Biovitrum (Sweden) BL&H Co Ltd (Better Life & Health) (South Korea) Orfadin® (nitisinone) tyrosinaemia type 1 (HT-1) Distribution Rare diseases
2011-01-11 Swedish Orphan Biovitrum (Sweden) BL&H Co Ltd (Better Life & Health) (South Korea) Kepivance® (palifermin). Swedish Orphan Biovitrum has acquired from Amgen the global rights for this modified version of human keratinocyte growth factor in September 2008. mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support Distribution Cancer Oncology
2011-01-11 Vivalis (France) Merial EB66® cell line for the manufacturing of a veterinary vaccine licensing Veterinary medicine